CCM-914

CCM-914 is a small-molecule translational readthrough-inducing drug (TRID) being developed for the treatment of genetic diseases caused by nonsense mutations (premature stop codons), specifically Cystic Fibrosis and Duchenne Muscular Dystrophy. Developed by CCM Biosciences through its CCM Protein Upregulation program, the compound is designed to promote the ribosomal readthrough of premature termination codons, thereby restoring the production of full-length, functional proteins. CCM-914 was acquired via exclusive licensing from the University of Palermo and the Italian Cystic Fibrosis Foundation. Preclinical evaluations in mouse and zebrafish models have indicated that the compound is non-toxic and possesses a superior safety and potency profile compared to earlier readthrough agents like ataluren. It is currently in the lead optimization phase of preclinical development.